Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AUTL01
- Development stage
- Unknown
- Lead developer
- Autolus Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AUTL01 is a preclinical **CAR-T cell therapy** being developed by **Autolus** in collaboration with **Noile-Immune**. The program is listed as a co-pipeline asset on Noile-Immune's pipeline and is directed against an **undisclosed tumor antigen**. Based on the disclosed collaboration context, the product is intended to mediate **T cell-driven tumor cell killing** and is likely designed using Noile-Immune's **PRIME CAR-T** platform features, which are intended to enhance CAR-T cell proliferation and trafficking, particularly for solid tumors, through secretion of IL-7 and CCL19. No disease indication, brand name, or precise molecular target has been publicly disclosed, and the program remains in **preclinical development**.
Beyond the preview
Go deeper on AUTL01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AUTL01.